|31.60||+0.4100||+1.31%||Vol 66.43K||1Y Perf 94.80%|
|Jul 30th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||45.00||Analyst Rating||Strong Buy 1.00|
|Potential %||42.41||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 52.56|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||760.86M||Earnings Rating||Sell|
|Price Range Ratio 52W %||75.21||Earnings Date||4th Aug 2021|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Q01 2020||-0.02||-0.63||-3 050.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2021|
|Estimated EPS Next Report||-0.72|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||92.74K|
|Avg. Monthly Volume||212.26K|
|Avg. Quarterly Volume||108.61K|
Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 31.6 per share at the end of the most recent trading day (a 1.31% change compared to the prior day closing price) with a volume of 66.43K shares and market capitalization of 760.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.
The one-year performance of Bicycle Therapeutics plc stock is 94.8%, while year-to-date (YTD) performance is 76.04%. BCYC stock has a five-year performance of %. Its 52-week range is between 15.25 and 36.99, which gives BCYC stock a 52-week price range ratio of 75.21%
Bicycle Therapeutics plc currently has a PE ratio of -12.50, a price-to-book (PB) ratio of 5.85, a price-to-sale (PS) ratio of 87.36, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.93%, a ROC of -42.80% and a ROE of -48.78%. The company’s profit margin is -%, its EBITDA margin is -492.90%, and its revenue ttm is $9.50 Million , which makes it $0.39 revenue per share.
Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is 04th Aug 2021.
The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1), with a target price of $45, which is +42.41% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bicycle Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.00, ATR14 : 2.01, CCI20 : -86.17, Chaikin Money Flow : 0.03, MACD : 0.51, Money Flow Index : 87.59, ROC : -6.56, RSI : 43.72, STOCH (14,3) : 21.20, STOCH RSI : 0.09, UO : 44.26, Williams %R : -78.80), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Kate Bingham (Sold 44 895 shares of value $1 526 466 ), Kevin Lee (Option Excercise at a value of $2 308 348), Kevin Lee (Sold 194 882 shares of value $6 217 756 ), Nicholas Keen (Sold 30 000 shares of value $934 843 ), Nigel Crockett (Option Excercise at a value of $945 474), Nigel Crockett (Sold 80 000 shares of value $2 592 140 ), Pierre Legault (Option Excercise at a value of $394 837), Pierre Legault (Sold 45 000 shares of value $1 382 621 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.